Ozomet-PG 1 Tablet is a combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Pioglitazone (15mg), indicated for the management of type 2 diabetes mellitus. This formulation synergistically improves glycemic control through complementary mechanisms of action. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake in muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to increased glucose utilization and decreased insulin resistance in adipose tissue, muscle, and the liver. The combination is particularly beneficial for patients inadequately controlled on monotherapy or dual therapy, offering improved efficacy in glycemic management. Ozomet-PG 1 Tablet should be administered as part of a comprehensive diabetes care plan including diet, exercise, and regular blood glucose monitoring. Caution is advised in patients with hepatic, renal, or cardiovascular impairment, and monitoring for potential adverse effects such as hypoglycemia, lactic acidosis, and fluid retention is recommended. This medication should be prescribed and used under medical supervision.